US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Devout Christian doctor, 68, who punched dementia
An 'arrogant' doctor who punched a vulnerable patient for making a racist comment and spitting at hi2024-05-21GOP runoffs to determine nominees for Congress, lieutenant governor and auditor
RALEIGH, N.C. (AP) — What is expected to be a very small group of North Carolina voters will decide2024-05-21- Chilling audio has emerged of the moment a British Airways captain was told to cancel takeoff becaus2024-05-21
Arrow McLaren selects Pourchaire as replacement driver for the injured Malukas
INDIANAPOLIS (AP) — Arrow McLaren named reigning F2 champion Theo Pourchaire as the permanent replac2024-05-21Christopher Reeve Super/Man documentary
Christopher Reeve documentary - Super/Man: The Christopher Reeve story - is set to be released in ci2024-05-21Arrow McLaren selects Pourchaire as replacement driver for the injured Malukas
INDIANAPOLIS (AP) — Arrow McLaren named reigning F2 champion Theo Pourchaire as the permanent replac2024-05-21
atest comment